Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Effects of acute exercise and allopurinol administration on soluble urokinase plasminogen activator receptor (suPAR).

Sanchis-Gomar F, Bonaguri C, Pareja-Galeano H, Gomez-Cabrera MC, Candel J, Viña J, Lippi G.

Clin Lab. 2013;59(1-2):207-10.

PMID:
23505929
2.

Effects of acute exercise and xanthine oxidase inhibition on novel cardiovascular biomarkers.

Sanchis-Gomar F, Bonaguri C, Aloe R, Pareja-Galeano H, Martinez-Bello V, Gomez-Cabrera MC, Candel J, Viña J, Lippi G.

Transl Res. 2013 Aug;162(2):102-9. doi: 10.1016/j.trsl.2013.02.006. Epub 2013 Mar 16.

PMID:
23507375
3.

Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.

Zimmermann HW, Reuken PA, Koch A, Bartneck M, Adams DH, Trautwein C, Stallmach A, Tacke F, Bruns T.

J Intern Med. 2013 Jul;274(1):86-100. doi: 10.1111/joim.12054. Epub 2013 Mar 17.

4.

Serum soluble urokinase plasminogen activator receptor (suPAR) in early pregnancy prior to clinical onset of preeclampsia.

Odden N, Henriksen T, Mørkrid L.

Acta Obstet Gynecol Scand. 2012 Oct;91(10):1226-32. doi: 10.1111/j.1600-0412.2012.01504.x. Epub 2012 Aug 21.

PMID:
22774918
5.
6.

Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.

Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB.

J Intern Med. 2010 Sep;268(3):296-308. doi: 10.1111/j.1365-2796.2010.02252.x. Epub 2010 May 28.

7.

Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.

Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F.

Liver Int. 2012 Mar;32(3):500-9. doi: 10.1111/j.1478-3231.2011.02665.x. Epub 2011 Oct 17.

PMID:
22098627
9.
10.
11.
12.

The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.

Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F.

Cancer Res. 1998 May 1;58(9):1843-9.

14.

[Can mannose-binding lectin and plasma level of soluble urokinase receptor be used in diagnosis and treatment monitorization of brucellosis patients?].

Karsen H, Cesur S, Karaağaç L, Binici I, Fidan Y, Oğüş E, Demiröz AP.

Mikrobiyol Bul. 2012 Jul;46(3):519-21. Turkish.

PMID:
22951667
15.
16.

Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.

Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N.

J Natl Cancer Inst. 1999 May 19;91(10):869-74.

PMID:
10340907
17.

Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.

Ostrowski SR, Piironen T, Høyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H.

Scand J Immunol. 2005 Apr;61(4):347-56.

18.

Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease.

Kolho KL, Valtonen E, Rintamäki H, Savilahti E.

Scand J Gastroenterol. 2012 Sep;47(8-9):951-5. doi: 10.3109/00365521.2012.699549. Epub 2012 Jul 2.

PMID:
22746351
19.

Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.

Lomholt AF, Christensen IJ, Høyer-Hansen G, Nielsen HJ.

Acta Oncol. 2010 Aug;49(6):805-11. doi: 10.3109/0284186X.2010.491086.

PMID:
20524776
20.

Supplemental Content

Support Center